Pfizer Ltd. — Capital/Financing Update 2025

Feb 21, 2025

==> picture [100 x 42] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

February 21, 2025

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

Pursuant to the Regulation 30 of the Listing Regulations, we hereby inform that, the Board of Directors of the Company at their Meeting held today, that commenced on February 20, 2025 at 11.00 a.m. and concluded on February 21, 2025 at 1.45 p.m have approved a proposal today, to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited (“Mylan”) for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane.

The additional details required to be disclosed, pursuant to the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as Annexure A.

We request you to kindly take the same on record.

Thanking you,

Your truly, For Pfizer Limited PRAJEET Digitally signed by PRAJEET NAIR NAIR Date: 2025.02.21 13:59:03 +05'30' Prajeet Nair

Director – Corporate Services & Company Secretary

Encl: a/a

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in

ANNEXURE – A

Additional information pursuant to SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr.No.	Particulars	Details
1.	Name of the entity	Mylan Pharmaceuticals Private Limited
2.	Area of agreement	Marketing and Sale of two brands of the CompanyAtivan and Pacitane.
3.	Domestic/international	Domestic
4.	Share exchange ratio / JV ratio	Not applicable
5.	Scope of business operation	Marketing and Sale of two brands of theCompany, Ativan and Pacitane.
6.	Details of consideration paid /received in agreement	Commercial terms as may be agreed between theparties.
7.	Significant terms and conditions ofagreement	Marketing and supply agreement for a period of5 (five) years within the territory of India.
8.	Whether the acquisition would fallwithin related party transactions andwhether the promoter/ promotergroup/ group companies have anyinterest in the entity being acquired.If yes, nature of interest and detailsthereof and whether the same isdone at arm’s length.	Not Applicable
9.	Size of the entity	Not Applicable
10	. Rationale and benefit expected	Mylan has a good presence in Central NervousSystem therapy area with skilled resources forengagement with super specialists namelyNeurologist and Psychiatrist.This arrangement with Mylan will enhancedistribution and in clinic presence of the productsof the Company.